POMC and TP53 genetic variability and risk of basal cell carcinoma of skin: Interaction between host and genetic factors

Journal of Dermatological Science

Volumn 63, Issue 1, 2011, Pages 47-54

  Rizzato, Cosmeri ^a   Scherer, Dominique ^a   Rudnai, Peter ^b   Gurzau, Eugen ^c   Koppova, Kvetoslava ^d   Hemminki, Kari ^a,e   Canzian, Federico ^a   Kumar, Rajiv ^a   Campa, Daniele ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH   (Hungary)

^c Environmental Health Center   (Romania)

^d State Health Institute   (Slovakia)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Basal cell carcinoma of the skin; P53; POMC; Single nucleotide polymorphism

Indexed keywords

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; POMC GENE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN COLOR; SUN EXPOSURE; SUNLIGHT; TP53 GENE;

AGED; CARCINOMA, BASAL CELL; CASE-CONTROL STUDIES; EUROPE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PRO-OPIOMELANOCORTIN; RECEPTOR, MELANOCORTIN, TYPE 1; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; SKIN PIGMENTATION; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 79957579743     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2011.03.006     Document Type: Article

References (40)

1. Miller D.L., Weinstock M.A. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994, 30(5, Part 1):774-778.
2. Kumar R. Molecular epidemiology of skin cancer. Prevention of skin cancer 2006, 225-240. Informa Healthcare, London. U. Ringborg, Y. Brandeber, E. Breitbart (Eds.).
3. Armstrong B.K., Kricker A., English D.R. Sun exposure and skin cancer. Australias J Dermatol 1997, 38(Suppl. 1):S1-6.
4. Brash D.E. Sunlight and the onset of skin cancer. Trends Genet 1997, 13:410-414.
5. English D.R., Armstrong B.K., Kricker A., Fleming C. Sunlight and cancer. Cancer Causes Control 1997, 8:271-283.
6. Lin J.Y., Fisher D.E. Melanocyte biology and skin pigmentation. Nature 2007, 445:843-850.
7. Schauer E., Trautinger F., Katilde¶ck A., Schwarz A., Bhardwaj R., Simon M., et al. Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest 1994, 93:2258-2262.
8. Hussain S.P., Hollstein M.H., Harris C.C. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis molecular epidemiology, and human risk assessment. Ann N Y Acad Sci 2000, 919:79-85.
9. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002, 19:607-614.
10. Cui R., Widlund H.R., Feige E., Lin J.Y., Wilensky D.L., Igras V.E., et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007, 128:853-864.
11. Tilli C.M., Van Steensel M.A., Krekels G.A., Neumann H.A., Ramaekers F.C. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol 2005, 152:1108-1124.
12. Garritano S., Gemignani F., Voegele C., Nguyen-Dumont T., Le Calvez-Kelm F., De Silva D., et al. Determining the effectiveness of high resolution melting analysis for SNP genotyping and mutation scanning at the TP53 locus. BMC Genet 2009, 10:5.
13. Whibley C., Pharoah P.D., Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009, 9:95-107.
14. Almquist L.M., Karagas M.R., Christensen B.C., Welsh M.M., Perry A.E., Storm C., et al. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer. Carcinogenesis 2011, 32:327-330.
15. Bendesky A., Rosales A., Salazar A.M., Sordo M., Peniche J., Ostrosky-Wegman P. p53 codon 72 polymorphism, DNA damage and repair, and risk of non-melanoma skin cancer. Mutat Res 2007, 619:38-44.
16. Chen Y.C., Xu L., Guo Y.L., Su H.J., Hsueh Y.M., Smith T.J., et al. Genetic polymorphism in p53 codon 72 and skin cancer in southwestern Taiwan. J Environ Sci Health A: Tox Hazard Subst Environ Eng 2003, 38:201-211.
17. Han J., Cox D.G., Colditz G.A., Hunter D.J. The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US Caucasian women. Mol Carcinogen 2006, 45:694-700.
18. Nan H., Kraft P., Hunter D.J., Han J. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer 2009, 125:909-917.
19. Scherer D., Bermejo J.L., Rudnai P., Gurzau E., Koppova K., Hemminki K., et al. MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism. Int J Cancer 2008, 122:1787-1793.
20. Lindberg A.L., Goessler W., Gurzau E., Koppova K., Rudnai P., Kumar R., et al. Arsenic exposure in Hungary, Romania and Slovakia. J Environ Monit 2006, 8:203-208.
21. Thirumaran R.K., Bermejo J.L., Rudnai P., Gurzau E., Koppova K., Goessler W., et al. Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin. Carcinogenesis 2006, 27:1676-1681.
22. Carlson C.S., Eberle M.A., Rieder M.J., Yi Q., Kruglyak L., Nickerson D.A. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004, 74:106-120.
23. Barrett J.C., Fry B., Maller J., Daly M.J., Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
24. de Bakker P.I., Yelensky R., Pe'er I., Gabriel S.B., Daly M.J., Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005, 37:1217-1223.
25. Lazar V., Hazard F., Bertin F., Janin N., Bellet D., Bressac B. Simple sequence repeat polymorphism within the p53 gene. Oncogene 1993, 8:1703-1705.
26. Canzian F., Cox D.G., Setiawan V.W., Stram D.O., Ziegler R.G., Dossus L., et al. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet 2010, 19:3873-3884.
27. Stram D.O., Haiman C.A., Hirschhorn J.N., Altshuler D., Kolonel L.N., Henderson B.E., et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the multiethnic cohort study. Hum Hered 2003, 55:27-36.
28. Gao X., Starmer J., Martin E.R. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol 2008, 32:361-369.
29. Marylyn D.R., Lance W.H., Jason H.M. Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 2003, 24:150-157.
30. Moore J.H. Computational analysis of gene-gene interactions using multifactor dimensionality reduction. Expert Rev Mol Diagn 2004, 4:795-803.
31. Ritchie M.D., Hahn L.W., Roodi N., Bailey L.R., Dupont W.D., Parl F.F., et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001, 69:138-147.
32. Cartharius K., Frech K., Grote K., Klocke B., Haltmeier M., Klingenhoff A., et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005, 21:2933-2942.
33. Boldrini L., Gisfredi S., Ursino S., Lucchi M., Greco G., Mussi A., et al. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis. Cancer Invest 2008, 26:168-172.
34. Gemignani F., Moreno V., Landi S., Moullan N., Chabrier A., Gutierrez-Enriquez S., et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004, 23:1954-1956.
35. Wang-Gohrke S., Weikel W., Risch H., Vesprini D., Abrahamson J., Lerman C., et al. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer 1999, 81:179-183.
36. Nan H., Qureshi A.A., Hunter D.J., Han J. Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk. Br J Dermatol 2008, 159:314-321.
37. Garcia-Closas M., Kristensen V., Langerod A., Qi Y., Yeager M., Burdett L., et al. Common genetic variation in TP53 and its flanking genes WDR79 and ATP1B2, and susceptibility to breast cancer. Int J Cancer 2007, 121:2532-2538.
38. Koshiol J., Hildesheim A., Gonzalez P., Bratti M.C., Porras C., Schiffman M., et al. Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited. Cancer Epidemiol Biomarkers Prev 2009, 18:1631-1637.
39. Schildkraut J.M., Iversen E.S., Wilson M.A., Clyde M.A., Moorman P.G., Palmieri R.T., et al. Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS One 2010, 5:e10061.
40. Mahmoudi S., Henriksson S., Corcoran M., Mendez-Vidal C., Wiman K.G., Farnebo M. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell 2009, 33:462-471.